A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma

Author(s): Annalisa Mercurio , Giulia Adriani , Alessia Catalano , Alessia Carocci , Luigia Rao , Giovanni Lentini , Maria M. Cavalluzzi , Carlo Franchini , Angelo Vacca , Filomena Corbo *.

Journal Name: Current Medicinal Chemistry

Volume 24 , Issue 25 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

Thalidomide is a drug with interesting therapeutic properties but also with severe side effects which require a careful and monitored use. Potential immunomodulatory, antiinflammatory, anti-angiogenic and sedative properties make thalidomide a good candidate for the treatment of several diseases such as multiple myeloma. Through an increase in the degradation of TNFα-mRNA, thalidomide reduces the production of TNFα by monocytes and macrophages stimulated by lipopolysaccharide or by T lymphocytes induced by mitogenic stimuli. The decreased level of TNFα alters the mechanisms of intracellular transduction by preventing the activation of NF-kB and by decreasing the synthesis of proteins, in particular IL-6, involved in cell proliferation, inflammation, angiogenesis and protection from apoptosis. Furthermore, thalidomide affects VEGF levels by down-regulating its expression. Nowadays, new safer and less toxic drugs, analogs of thalidomide, are emerging as beneficial for a more targeted treatment of multiple myeloma and several other diseases such as Crohn's disease, rheumatoid arthritis, sarcoidosis, erythema nodosum leprosum, graft-versus-host disease.

Keywords: Thalidomide, angiogenesis, TNF-α, IL-6, VEGF, thalidomide analogs.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 24
ISSUE: 25
Year: 2017
Page: [2736 - 2744]
Pages: 9
DOI: 10.2174/0929867324666170601074646
Price: $58

Article Metrics

PDF: 70
HTML: 15
EPUB: 3